Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719).
Francolini G, Bertini N, Di Cataldo V, Garlatti P, Aquilano M, Caini S, Bruni A, Ingrosso G, D'angelillo RM, Tagliaferri L, Augugliaro M, Triggiani L, Parisi S, Timon G, Arcidiacono F, Marvaso G, Jereczek-Fossa BA, Lancia A, Franzese C, Alongi F, Simontacchi G, Greto D, Bonomo P, Loi M, Frosini G, Burchini L, Desideri I, Meattini I, Valicenti RK, Livi L.
Francolini G, et al. Among authors: d angelillo rm.
Prostate Cancer Prostatic Dis. 2025 Dec;28(4):908-912. doi: 10.1038/s41391-025-00950-3. Epub 2025 Feb 19.
Prostate Cancer Prostatic Dis. 2025.
PMID: 39972049
Clinical Trial.